Bone Morphogenetic Protein (BMP) is a group of highly conserved functional proteins with similar structure, belonging to the TGF-β family. In 1889, Senn used demineralized bone for the first time to repair inflammatory bone defects in humans and dogs, proving that demineralized bovine bone could be used to treat osteomyelitis. In 1931, Huggins discovered that the epidermis of the urinary tract could induce new bone formation by ectopic position and reported the experimental process of bone induction for the first time. In 1945, Lacroix extracted Osteoblast from bone, which can induce rabbit muscle osteogenesis, and proposed the hypothesis of bone induction and named it as osteogenic protein. In 1965, Urist found that muscle mesenchymal cells could be transformed into bone system cells by injecting decalcified bone matrix gelatin into muscle, resulting in ectopic osteogenesis. Urist suggested that the decalculated bone may contain an inducer that induces the transformation of mesenchymal cells swimming around blood vessels into irreversible osteoid cells that produce cartilage and bone tissue in bone and beyond. The inducer is bone morphogenetic protein.
With
the development of molecular biology and genetic engineering, Wozney et al.
first carried out cDNA cloning of BMP in 1988. They cloned cDNA of HBMP-1,
BMP-2A (BMP-2), BMP-2B (BMP-4) and BMP-3 using recombinant DNA technology. And
expressed in eukaryotic and prokaryotic cells of Escherichia coli. In 1990,
Celeste et al. reported the cloning of BMP-5, BMP-6, and BMP-7, and suggested
that the cloned BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, and BMP-7 should be named
respectively.
BMP
can stimulate DNA synthesis and cell replication, thereby promoting the
directed differentiation of mesenchymal cells into osteoblasts. It is also the
main factor inducing bone and cartilage formation in vivo, and is expressed in
limb growth, endochondral ossification, early fracture, cartilage repair, and
plays an important role in bone embryonic development and regeneration repair. Now
there are 43 members of BMP family, widely existing in pig, cow, sheep, rabbit,
mouse and human embryo, blood cell, kidney, spleen and other tissues, and there
is a high homology between different species. BMP not only participates in the
regulation of bone, but also plays a role in the development of fat, kidney,
liver, bone and nervous system.
Get the complete sample, please click: https://www.globalmarketmonitor.com/reports/762806-bone-morphogenetic-protein-(bmp)-2-market-report.html
Research shows that North America is the largest revenue market in this industry. In 2020, the total revenue of the industry in North America was $460.30 million, with a market share of 93.60%, indicating a high degree of geographic concentration in the global bone morph protein industry. However, according to our forecast, this situation will slowly break down in the coming years, with the North American market gradually decreasing over the forecast year, while the market share of Asia-Pacific region will gradually increaseThe market share of North America in the industry is expected to decline to 76.04% by 2026, while Asia-Pacific market share will rise to 17.02%. Investment in a certain region mainly needs to consider whether there is a large market potential. However, since many regions have very strict regulations on product markets, we recommend starting with regions with market access. The legal supervision of BMP-2 products in the American market is relatively perfect, and the market awareness is relatively high. Therefore, investment in the American market can be considered. Meanwhile, over the past few years, the economic development of the Asia-Pacific region, the growth of healthcare affordability and the improvement of healthcare facilities represent the region\'s future development potential. Therefore, we also recommend considering investment in this area.
Future Development Opportunities and Challenges for
Global Bone Morphogenetic Protein Industry
In
recent years, aging, sports-related injuries and sedentary lifestyles in many
regions have led to an increase in spinal fusion and joint reconstruction procedures.
Local growth factors play a leading role in the regulation of bone tissue
formation, especially BMP-2, as a growth factor, can independently induce the
differentiation of mesenchymal cells into bone tissue, and is a key regulatory
factor in the process of bone tissue formation.
In addition, BMP-2 is of great help in patients undergoing spinal
perfusion therapy, reducing pain, reducing dependence on screws and spinal
rods, and increasing the rate of spinal fusion. Market participants are
committed to product innovation and product line expansion, and the application
scope will be more extensive in the future.
On the other hand, although BMP-2 is widely used in the United States
and Europe, it is less used in other emerging markets. With the improvement of
market awareness of BMP-2, it is expected to gain more development
opportunities in emerging markets.
However, currently, the use of BMP-2 is subject to strict regulatory restrictions and will face similar problems in the future. In addition, controversy over side effects of BMP-2 and negative press related to the product will also hinder market expansion to some extent.
Get the complete sample, please click: https://www.globalmarketmonitor.com/reports/762806-bone-morphogenetic-protein-(bmp)-2-market-report.html
We provide more professional and intelligent market reports to complement your business decisions.
Chinese
